Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Buy at Societe Generale

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by Societe Generale from a “hold” rating to a “buy” rating in a research note issued on Friday, Marketbeat reports.

Several other research firms have also commented on FMS. Citigroup assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 1st. They set a “neutral” rating for the company. Morgan Stanley upped their price target on shares of Fresenius Medical Care AG & Co. KGaA to €40.50 ($43.55) in a report on Wednesday, August 16th. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 3rd. UBS Group upgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “neutral” rating in a research report on Wednesday, September 13th. Finally, Truist Financial reduced their price target on Fresenius Medical Care AG & Co. KGaA from $28.00 to $24.00 and set a “hold” rating on the stock in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.40.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $19.27 on Friday. The company’s 50-day moving average price is $19.36 and its 200-day moving average price is $22.43. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.47. The company has a market cap of $11.31 billion, a PE ratio of 23.49 and a beta of 1.04. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $14.82 and a twelve month high of $27.72.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.06). The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.42 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 4.85% and a net margin of 2.30%. During the same period in the previous year, the firm earned $0.40 earnings per share. On average, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 20.5% in the first quarter. Dodge & Cox now owns 4,223,110 shares of the company’s stock valued at $89,783,000 after purchasing an additional 718,910 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 77.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,570,817 shares of the company’s stock worth $25,667,000 after buying an additional 683,851 shares during the period. Morgan Stanley lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 3.7% in the 3rd quarter. Morgan Stanley now owns 1,041,447 shares of the company’s stock worth $22,433,000 after buying an additional 36,820 shares during the period. Balyasny Asset Management L.P. grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 69.5% during the 1st quarter. Balyasny Asset Management L.P. now owns 750,610 shares of the company’s stock worth $15,958,000 after buying an additional 307,801 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 58.8% during the second quarter. Goldman Sachs Group Inc. now owns 736,847 shares of the company’s stock valued at $17,633,000 after buying an additional 272,886 shares during the period. 5.81% of the stock is currently owned by institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.